Downregulation of cell cycle modulators p21, p27, p53, Rb and proapoptotic Bcl-2-related proteins Bax and Bak in cutaneous melanoma is associated with worse patient prognosis: Preliminary findings

Journal of Cutaneous Pathology

Volumn 34, Issue 3, 2007, Pages 247-256

  Tchernev, Georgi ^a,b   Orfanos, C E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CELL CYCLE PROTEIN; MOLECULAR MARKER; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RISK; CELL CYCLE REGULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DOWN REGULATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; MELANOMA; METASTASIS; METASTASIS POTENTIAL; PREDICTION; PROGNOSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; RISK ASSESSMENT; THICKNESS;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; DOWN-REGULATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33846921781     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00700.x     Document Type: Article

References (54)

1. Meier F, Satyamoorthy K, Nesbit M, et al. Molecular events in melanoma development and progression. Front Biosci 1998; 3: 1005.
2. Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev 1990; 9: 101.
3. Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene CDKN2 as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994; 8: 23.
4. INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996; 12: 97.
5. Nancarrow DJ, Mann GJ, Holland EA, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993; 53: 936.
6. Gruis NA, Sandkuijl LA, Weber JL, et al. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 1993; 3: 271.
7. Goldstein AM, Dracopoli NC, Engelstein M, Fraser MC, Clark WH Jr, Tucker MA. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet 1994; 54: 489.
8. Mac Geoch C, Bishop JA, Bataille V, et al. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 1994; 3: 2195.
9. Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436.
10. ARF, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713.
11. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725.
12. Li G, Tang L, Zhou X, Tron V, Ho V. Chemotherapy-induced apoptosis in melanoma cells is p53 dependent. Melanoma Res 1998; 8: 17.
13. Raffo AJ, Kim AL, Fine RL. Formation of nuclear Bax/p53 complexes is associated with chemotherapy induced apoptosis. Oncogene 2000; 19: 6216.
14. Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22: 9030.
15. Hussein MR. The TP53 tumour suppressor gene and melanoma tumourigenesis: is there a relationship? Tumour Biol 2004; 25: 200.
16. Hussein MR, Haemel AK, Sudilovsky O, Wood GS. Genomic instability in radial growth phase melanoma cell lines after ultraviolet irradiation. J Clin Pathol 2005; 58: 389.
17. INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291.
18. Sviderskaya EV, Gray-Schöpfer VC, et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis and immortilization: possible implications for melanoma progression. J Natl Cancer Inst 2003; 95: 723.
19. Rodolfo M, Daniotti M, Vallacchi V. Genetic progression of metastatic melanoma. Cancer Letter 2004; 214: 133.
20. Funk J, Kind P. Cell cycle control, genetic instability and cancer. Hautarzt 1997; 48: 157.
21. Halaban R, Miglarese MR, Smicun Y, Puig S. Melanomas, from cell cycle point of view. Int J Mol Med 1998; 1: 419.
22. INK4a confers susceptibility to metastatic melanoma in mice. Nature 2001; 413: 83.
23. Piepkorn M. Melanoma genetics: an update with focus on the CDK2A(p16)/ARF tumor supressors. J Am Acad Dermatol 2000; 42: 705.
24. Fecker L, Geilen C, Tchernev G, et al. Loss of proapoptotic Bcl-2 related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol 2006; 126: 1366.
25. Daniel PT, Schulze-Osthoff K, Belka C, Guner D. Guardians of cell death: the Bcl-2 family proteins. Essays Biochem 2003; 39: 73.
26. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342
27. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998; 153: 305.
28. Van den Oord JJ, Vandeghinste N, De Ley M, et al. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294.
29. Stefanaki C, Antoniou C, Stefanaki K, et al. Bcl-2 and Bax in congenital naevi. Br J Dermatol 2006; 154: 1175.
30. Poyraz A, Akyurek N, Gonul II, Erdem O. p21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters. J Exp Clin Cancer Res 2004; 23: 625.
31. Murphy M, Mabruk MJ, Lenane P, et al. The expression of p53, p21, Bax and induction of apoptosis in normal volunteers in response to different doses of ultraviolet radiation. Br J Dermatol 2002; 147: 110.
32. Cristofolini M, Boi S, Girlando S, et al. p53 protein expression in nevi and melanomas. Arch Dermatol 1993; 129: 739.
33. Weiss J, Heine M, Korner B, Pilch H, Jung EG. Expression of p53 protein in malignant melanoma: clinico-pathological and prognostic implications. Br J Dermatol 1995; 133: 23.
34. INK4a expression. An Otorrinolaringol Ibero Am 2001; 28: 303.
35. Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutaneous melanoma; a case- control study. Int J Cancer 1998; 77: 843.
36. Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Therapy 2002; 9: 807.
37. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992; 151: 237.
38. Mc Gregor JM, Yu CC, Dublin EA, Barnes DM, Levison DA, Mac Donald DM. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993; 128: 606.
39. Loggini B, Rinaldi I, Pingitore R, Cristofani R, Castagna M, Barachini P. Immunohistochemical study of 49 cutaneous melanomas: p53, PCNA, Bcl-2 expression and multidrug risistance. Tumori 2001; 87: 179.
40. Lassam NJ, From L, Kahn HJ. Overexpression of p53 is a late event in the development of malignant melanoma. Cancer Res 1993; 53: 2235.
41. Sparrow LE, English DR, Heenan PJ, Dawkins HJ, Taran J. Prognostic significance of p53 overexpression in thin melanomas. Melanoma Res 1995; 5: 387.
42. Yamamoto M, Takahashi H, Saitoh K, Horikoshi T, Takahashi M. Expression of the p53 protein in malignant melanomas as a prognostic indicator. Arch Dermatol Res 1995; 287: 146.
43. Wang JY, Ki SW. Choosing between growth arrest and apoptosis through the retinoblastoma tumour suppressor protein, Abl and p73. Biochem Soc Trans 2001; 29: 666.
44. Bartkova J, Lukas J, Guldberg P, et al. The p16-cyclin D/CdK4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. Cancer Res 1996; 56: 5475.
45. Cordon-Cardo C, Richon VM. Expression of the retinoblastoma protein is regulated in normal human tissues. Am J Pathol 1994; 144: 500.
46. Korabiowska M, Ruschenburg I, Betke H, et al. Downregulation of the retinoblastoma gene expression in the progression of malignant melanoma. Pathobiology 2001; 69: 274.
47. Daniel PT, Wieder T, Sturm I, Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001; 15: 1022.
48. Krajewski S, Blomqvist C, Franssila K, et al. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 1995; 55: 4471.
49. Friess H, Lu Z, Graber HU, et al. Bax, but not bcl-2, influences the prognosis of human pancreatic cancer. Gut 1998; 43: 414.
50. Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. Bax protein expression and clinical outcome in epithelial ovarial cancer. J Clin Oncol 1998; 16: 2583.
51. Guner D, Sturm I, Hemmati P et al. Multigene analysis of Rb pathway and apoptosis control in esophageal squamous cell carcinoma identifies patients with good prognosis. Int J Cancer 2003; 103: 445.
52. INK4a/CDKN2 identifies patients with good prognosis. J Clin Oncol 2001; 19: 2272.
53. Korabiowska M, Brinck U, Ruschenburg I, Schlott T, Droese M, Stachura J. Bcl-2 and Bax-expression in naevi and melanomas and their relation to ploidy status and proliferation. Pol J Pathol 1999; 50: 17.
54. Tang, L, Tron VA, Reed JC, et al. Expression of apoptosis regulators in cutaneous malignant melanoma. Clin Cancer Res 1998; 4: 1865.